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Abstract
Purpose Although quality of life (QoL) is improved in patients with acromegaly after disease control, QoL correlates only
weakly with traditional biomarkers. Our objective is to investigate a potential relation between the new serum biomarker
soluble Klotho (sKlotho), GH and insulin-like growth factor 1 (IGF-1) levels, and QoL.
Methods In this prospective cohort study, we investigated 54 acromegaly patients biochemically well-controlled on com-
bination treatment with first-generation somatostatin receptor ligands (SRLs) and pegvisomant (PEGV) at baseline and
9 months after switching to pasireotide LAR (PAS-LAR; either as monotherapy, n= 28; or in combination with PEGV,
n= 26). QoL was measured by the Patient-Assessed Acromegaly Symptom Questionnaire (PASQ) and Acromegaly Quality
of Life (AcroQoL) questionnaire.
Results Switching to PAS-LAR treatment significantly improved QoL without altering IGF-1 levels. QoL did not correlate
with GH or IGF-1 levels, but sKlotho correlated with the observed improvements in QoL by the AcroQoL global (r=
−0.35, p= 0.012) and physical subdimension (r=−0.34, p= 0.017), and with PASQ headache (r= 0.28, p= 0.048),
osteoarthralgia (r= 0.46, p= 0.00080) and soft tissue swelling score (r= 0.29, p= 0.041). Parallel changes in serum
sKlotho and IGF-1 (r= 0.31, p= 0.023) suggest sKlotho and IGF-1 to be similarly dependent on GH. Comparing the PAS-
LAR combination therapy and the monotherapy group we did not observe a significant difference in improvement of QoL.
Conclusions Patients experienced improved QoL during PAS-LAR, either as monotherapy or in combination with PEGV.
Soluble Klotho concentrations appear to be a useful marker of QoL in acromegaly patients but the underlying mechanisms
remain to be investigated.
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ULN Upper limit of normal
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Introduction
Medical treatment of acromegaly with the combination of
the second-generation somatostatin receptor ligand (SRL)
pasireotide long-acting release (PAS-LAR) and the GH
receptor antagonist, pegvisomant (PEGV) provides control
of insulin-like growth factor I (IGF-1) levels in most
(77.0%) patients [1, 2]. To this date, GH and especially GH
activity, as reflected (in part) by IGF-1 concentrations in
serum, are considered the ‘classical’ biomarkers to diagnose
acromegaly and monitor disease activity during treatment.
Normalization of GH and IGF-1 levels has been associated
with normalization in mortality rates [3–6], while not
necessarily reflecting optimal quality of life (QoL) in
acromegalic patients [7–11].
The Klotho gene was originally identified as an ageing-
suppressor gene of restricted expression (predominantly in
the kidney, brain, and parathyroid and pituitary glands),
encoding a transmembrane protein, mKlotho. The extra-
cellular domain of mKlotho is found as a circulating soluble
α-Klotho (sKlotho) into blood, cerebrospinal fluid, and
urine [12, 13]. Recent data suggest that sKlotho levels are
elevated in patients with active acromegaly [14, 15]. After
surgical removal of the GH-producing pituitary adenoma
alone or in combination with first-generation SRLs they
decrease toward the normal range [14–17]. Overall, when
assessing patients with acromegaly, concomitant and par-
allel changes in serum sKlotho and IGF-1 were observed
over time in each patient, and levels of sKlotho and IGF-1
appeared to be similarly dependent on GH [14, 18]. How-
ever, the mechanisms by which acromegaly leads to excess
sKlotho remain to be elucidated. Further, sKlotho has been
proposed to inhibit IGF-1 and insulin receptor signaling by
inhibiting tyrosine phosphorylation of both receptors and
their downstream signaling proteins (i.e., IRS) [19–21].
Thus, sKlotho seems to be a new player in the intricate
regulation of the GH and IGF-1 axis. As sKlotho con-
centrations appear to reflect acromegaly disease activity
[14, 15], it may potentially serve as a more integrated serum
biomarker of disease-specific QoL.
Normalized GH and IGF-1 levels do not always coincide
with symptom relief [11], which may be explained by
‘extra-hepatic acromegaly’ [22]. In addition to suppression
of GH secretion from the pituitary tumor, SRLs also sup-
press insulin secretion in the portal vein, which by itself
downregulates hepatic IGF-1 production via GH receptors.
However, the GH action in the peripheral tissues remains
unaltered and might still have acromegaly-inducing effects
[22]. In other words, integrated extra-hepatic GH activity
may remain elevated despite normalized serum IGF-1 levels
in these patients. If these extra-hepatic GH actions could be
antagonized by the addition of PEGV in patients using first-
or second-generation SRLs, one might observe an
improvement of QoL in comparison with SRL mono-
therapy. In fact, it has been shown previously that the
addition of PEGV to first-generation long-acting SRL
therapy can improve GH-dependent parameters of QoL
[23]. To date, however, there is no data about second-
generation SRL (i.e., PAS-LAR) and PEGV combination
therapy and its effect on QoL nor a convenient biomarker of
extra-hepatic disease activity in acromegaly.
We performed a prospective intervention study in well-
controlled acromegaly patients on first-generation SRLs and
PEGV combination therapy. Soluble Klotho, GH and IGF-1
levels, and QoL were assessed before and after switching to
PAS-LAR alone or PAS-LAR and PEGV combination
therapy for a period of 9 months. The rationale for initiating
the combination treatment is based on the concept that the
addition of PEGV could antagonize the so-called extra-
hepatic GH actions, and thereby improve QoL in compar-
ison with PAS-LAR monotherapy. Aims of the study are:
(1) to investigate the value of sKlotho in monitoring QoL;
(2) and to establish the QoL during PAS-LAR treatment,
and whether changes in disease activity can be differ-
entiated in the PAS-LAR monotherapy and combination
therapy group.
Materials and methods
Patients and study design
Data collection of acromegaly patients was performed at the
outpatient clinic of the Pituitary Center Rotterdam, Erasmus
University Medical Center in Rotterdam. We initially started
with a cohort of 61 patients who received PAS-LAR treat-
ment during their participation in the PAPE study (Fig. 1);
details of the study design have been reported previously
[1, 2]. Patients who received either PAS-LAR monotherapy
or combination therapy less than 4 months were excluded (7
of the 61, Fig. 1). Briefly, all patients were previously treated
with first-generation SRLs, followed by PEGV and first-
generation SRL combination therapy. At baseline, the PEGV
dose was reduced by 50% up to 3 months. When IGF-1
remained ≤1.2 × ULN after 3 months, patients were switched
to PAS-LAR 60mg monotherapy for 3 months. When IGF-
1 was >1.2 × ULN, patients were switched to PAS-LAR
60mg, and they continued with the 50% reduced PEGV
dose for three months. During the extension phase until
9 months of PAS-LAR treatment, the goal was to achieve
IGF-1 normalization (IGF-1 ≤ 1.2 × ULN) through protocol-
based dose titration of PEGV and PAS-LAR [1, 2].
We prospectively collected data on PAS-LAR, while
data on medical history and clinical response to patients
during first-generation SRLs treatment were retrospectively
collected.
Endocrine
Blood measurements
Total IGF-1 concentrations were measured by chemilumi-
nescent immunometric assay (IDS-iSYS; Immunodiagnos-
tic Systems, Boldon, United Kingdom) and were interpreted
according to the age- and sex-dependent ranges [24]. GH
levels were measured using the IDS-iSYS assay, which is
free of interference from PEGV [25]. Soluble α-Klotho
levels were assessed using a solid phase sandwich ELISA
described by Yamazaki et al. [26] (IBL; IBL International
GmbH, Hamburg, Germany) according to the manu-
facturer’s instructions. Absolute changes in IGF-1, GH, and
sKlotho were calculated by subtracting follow-up con-
centrations from concentrations at baseline.
QoL questionnaires
The Patient-Assessed Acromegaly Symptom Questionnaire
(PASQ) and Acromegaly Quality of Life (AcroQoL)
questionnaire were used to evaluate symptoms and QoL at
baseline and after 9 months of PAS-LAR treatment [27–30].
The PASQ is a disease-specific questionnaire, which
consists of six questions scoring 0–8 [31]. These questions
evaluate symptoms such as headache, excessive perspira-
tion, osteoarthralgia, fatigue, soft tissue swelling, and par-
esthesia. The seventh question addresses the overall health
status, based on the other six questions, scoring 0–10. The
maximum score is 48 and indicates severe signs and
symptoms.
The AcroQoL questionnaire comprises 22 questions,
with each having five possible answers scoring 1–5. The
questions are divided into two main categories: physical and
psychological function; the latter is subdivided into
appearance and personal relationships [27, 29]. The score of
110 (100%) reflects the best possible AcroQoL score. The
AcroQoL questionnaire has a good internal consistency
(Cronbach’s α > 0.7) [30].
Statistical analysis
For the analysis of QoL questionnaires, changes between
baseline and during 9 months of PAS-LAR treatment were
calculated (changes in QoL; i.e., subtracting follow-up from
baseline scores). To assess improvement in QoL scores
during the study, we used the minimally important differ-
ence (MID) to define improvement in QoL scores between
baseline and 9 months of PAS-LAR. MID is defined as an
improvement of >50% of the baseline standard deviation
(SD) of the baseline mean QoL score [28].
For missing data, imputation based on last observation
carried forward was used. Continuous data were expressed
as mean and SD or median and interquartile range (IQR), as
appropriate. Categorical data were represented as observed
frequencies and percentages. The Kolmogorov–Smirnov
test was used to determine normality of variables. Loga-
rithmic transformations were applied to variables that did
not meet the criteria of normality. We compared categorical
variables between the two groups with the χ2 test, con-
tinuous variables between groups with either the Student’s t
test or the Mann–Whitney U test and either the paired
Student’s t test or the Wilcoxon signed rank test for two
related groups. Correlation analyses were performed using
Spearman’s rank-correlation coefficient. P < 0.05 was con-
sidered statistically significant without any multiplicity
correction. Statistical analyses were performed using SPSS
software (version 24 for Windows; SPSS Inc., Chicago, IL)
and GraphPad Prism® version 6.04 (GraphPad Software,
San Diego, CA).
Fig. 1 Flowchart of the selection
procedure for the study cohort.
All patients eventually received
first-generation SRL and PEGV
combination treatment and were
switched to pasireotide LAR
treatment during the PAPE
study. PAPE pasireotide LAR
and pegvisomant study, PAS-
LAR pasireotide long-acting
release, PEGV pegvisomant,
SRL somatostatin
receptor ligand
Endocrine
Results
Clinical characteristics of study population
All 54 patients completed the study. Cohort demographics
and clinical characteristics are summarized in Table 1. After
3 months, 14 (25.9%) of 54 patients were on PAS-LAR
60 mg monotherapy every 4 weeks, increasing to 28
(51.9%) patients during 9 months of PAS-LAR treatment
(see Fig. 1 and Supplementary Fig. 1). The remaining 40
(74.1%) patients with elevated IGF-1 levels continued with
their reduced dose of PEGV treatment, but now in combi-
nation with PAS-LAR 60 mg, decreasing to 26 (48.1%)
patients during 9 months of PAS-LAR treatment At base-
line, the PEGV dose was significantly higher in the PAS-
LAR combination therapy group compared with the PAS-
LAR monotherapy group (median 160 mg/week [IQR
100–225] vs. 60 mg/week [60–80], p ≤ 0.0001). In the PAS-
LAR combination therapy group, the average total reduc-
tion in PEGV dose was 38.1% (median 80 mg/week [IQR
48–155] vs. 160 mg/week [100–225], p= 0.0031) after
9 months of PAS-LAR treatment.
At baseline, age and time since diagnosis of the patients
receiving PAS-LAR monotherapy were significantly higher
compared with the combination therapy group (age, mean
56.4 years [SD 11.7] vs. 50.0 years [11.3], p= 0.047; time
since diagnosis, median 10.5 years [IQR 6.3–15.0] vs. 7.0
years [2.0–11.0], p= 0.020).
Baseline sKlotho, GH and IGF-1 axis
At baseline, serum sKlotho levels were not significantly
different between patients receiving 9 months of PAS-
LAR mono- versus patients using PAS-LAR and PEGV
combination therapy (median 513 ng/L [IQR 445–627]
vs. 482 [443–660], p= 0.44, Fig. 2a). GH and total
IGF-1 levels at baseline were significantly higher in the
patients who did receive combination therapy during the
next 9 months when compared with patients who did
receive PAS-LAR monotherapy during the next
9 months (GH, median 6.3 µg/L [IQR 3.0–14.5] vs. 1.9
[0.6–5.0], p= 0.00030, Fig. 2b; total IGF-1, median
27.4 nmol/L [IQR 22.4–34.3] vs. 24.0 [20.9–29.6], p=
0.038; Fig. 2c). Serum IGF-1 (x upper limit of normal
(ULN)) levels at baseline, however, were not sig-
nificantly different between the two groups (median 0.90
[IQR 0.8–1.0] vs. 1.0 [0.9–1.1], p= 0.27; Fig. 2d) and
were within the age-adjusted normal range.
Table 1 Cohort demographics
and clinical characteristics of the
total group, PAS-LAR
monotherapy and combination
therapy subgroup
Clinical characteristics All patients
n= 54
PAS-LAR
monotherapy
n= 28
PAS-LAR and PEGV
combination therapy
n= 26
Age (years) 53.3 (11.9) 56.4 (11.7) 50.0 (11.3)*
Female patients 26 (48.1%) 15 (53.6%) 11 (42.3%)
Time since diagnosis (years) 8.5 (5.0–13.0) 10.5 (6.3–15.0) 7.0 (2.0–11.0)*
Previous treatment
Surgery 25 (46.3%) 16 (57.1%) 9 (34.6%)
Surgery and radiotherapy 6 (11.1%) 4 (14.3%) 2 (7.7%)
Primary medical therapy 29 (53.7%) 12 (42.9%) 17 (65.4%)
Pituitary insufficiency
Panhypopituitarism 3 (5.6%) 2 (7.1%) 1 (3.8%)
1–2 axes 25 (46.3%) 12 (42.9%) 13 (50.0%)
No hypopituitarism 26 (48.2%) 14 (50.0%) 12 (46.2%)
Duration of SRL+ PEGV treatment
(years)
5.9 (3.4–8.9) 7.0 (4.8–9.2) 4.5 (1.6–8.1)
PEGV dose (mg/week) at baseline 80 (60–160) 60 (60–80) 160 (100–225)*
Presence of diabetes during PAS-
LAR
38 (70.4%) 20 (71.4%) 18 (69.2%)
Insulin therapy during PAS-LAR 3 (5.6%) 1 (3.6%) 2 (7.7%)
Data are mean (SD), median (IQR) or number (%)
Asterisk represents p ≤ 0.05 for the comparisons between PAS-LAR monotherapy and PAS-LAR and PEGV
combination therapy and are derived from the Student’s t test (continuous variables) and Pearson’s χ2 test
(categorical variables)
IGF-1 insulin-like growth factor 1, PAS-LAR pasireotide long-acting release, PEGV pegvisomant, SRL
somatostatin receptor ligand
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Follow-up sKlotho, GH and IGF-1 axis
When comparing follow-up to baseline, we observed a
significant increase in sKlotho levels in the combination
therapy group (median 482 ng/L [IQR 443–660] vs. 603
[521–847], p= 0.0016, Fig. 2a), but no significant change in
the monotherapy group (513 [445–627] vs. 555.0
[440–671], p= 0.30, Fig. 2a). During follow-up, sKlotho
levels were not different between the two treatment groups.
Due to the PEGV dose reduction or discontinuation during
the study, GH levels were significantly lower in both groups
when compared with baseline (monotherapy, median
1.9 µg/L [IQR 0.6–5.0] vs. 0.6 [0.3–1.2], p= 0.0082; com-
bination therapy, 6.3 [3.0–14.5] vs. 2.7 [1.4–6.8], p=
0.0048, Fig. 2b). Total and age-dependent serum IGF-1
levels showed a significant increase between baseline and
follow-up in the combination therapy group (total IGF-1,
median 27.4 nmol/L [IQR 22.4–34.3] vs. 31.0 [25.1–36.7],
p= 0.016; IGF-1 (x ULN), median 1.0 [IQR 0.9–1.1] vs. 1.1
[0.9–1.3], p= 0.027, respectively Fig. 2c, d). No changes in
serum IGF-1 were seen in the monotherapy group.
As previously published by Muhammad et al. comparing
follow-up to baseline, total and age-dependent serum IGF-1
levels, as well as GH levels were significantly higher in
patients treated with combination therapy compared with
patients treated with monotherapy (total IGF-1, median
31.0 nmol/L [IQR 25.1–36.7] vs. 20.5 [15.4–26.3], p ≤
0.0001; IGF-1 (x ULN), median 1.1 [IQR 0.9–1.3] vs. 0.8
[0.7–1.0], p ≤ 0.0001, respectively Fig. 2c, d; GH, median
2.7 µg/L [IQR 1.4–6.8] vs. 0.6 [0.3–1.2], p= 0.0085,
Fig. 2b) [2].
Baseline QoL
The PASQ and AcroQoL scores of the total cohort at
baseline and follow-up are summarized in Table 2. At
baseline, the most severe symptoms of the PASQ were
osteoarthralgia and fatigue, whereas excessive perspiration,
soft tissue swelling, paresthesia, and headache were the
least burdensome. With regards to the AcroQoL score, the
greatest impairments were detected in the physical and
appearance subdimensions, while the personal relations and
total psychological subdimensions were the least impaired.
AcroQoL and PASQ scores were not significantly different
between the PAS-LAR mono- and combination therapy
group at baseline (Table 2).
Follow-up QoL
Significant differences in the total cohort between baseline
and during 9 months of PAS-LAR treatment were detected
in the individual PASQ scores for headache (Δ0, p=
0.014, MID 23.5%) and fatigue (Δ0, p= 0.0074, MID
25.5%). Improvements in the total PASQ score were of
borderline significance only (Δ− 4.0, p= 0.090) with a
MID of 33.3% of patients during 9 months of PAS-LAR
compared with baseline. Significant improvements were
observed in all AcroQoL subdimensions; physical (Δ4.3,
Fig. 2 Soluble Klotho (a) levels
and random GH (b) at baseline
and during PAS-LAR
monotherapy or in combination
with PEGV. IGF-1 (c) and
IGF-1 (x ULN) (d) levels at
baseline and during PAS-LAR
monotherapy or in combination
with PEGV. The white boxes
represent the PAS-LAR
monotherapy group, while the
gray boxes represent the PAS-
LAR and PEGV combination
therapy group. Box whisker
plots are expressed in minimum,
median, and maximum. Insulin-
like growth factor 1 IGF-1,
PAS-LAR pasireotide long-
acting release, sKlotho soluble
Klotho, ULN upper limit
of normal
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p ≤ 0.0001), psychological (Δ2.2, p= 0.0051), and
appearance (Δ2.8, p= 0.0095), except for personal rela-
tions. The greatest significant improvement was observed
in the physical subdimension, from 31.4% at baseline to
35.7% at 9 months (Δ4.3, p ≤ 0.0001) with a MID of
54.9% of patients. The AcroQoL global score also
improved significantly after treatment with PAS-LAR
during the study (Δ5.4, p ≤ 0.0001). In fact, 47.1% of the
patients experienced a MID.
Treatment group stratification
When stratifying the total cohort by therapy group (PAS-
LAR mono- and combination therapy), AcroQoL and
PASQ scores were not significantly different between the
PAS-LAR mono- and combination therapy group at base-
line or follow-up (data not shown). However, a MID in soft
tissue swelling during PAS-LAR treatment tended to pre-
sent more frequently in the combination group compared
with the monotherapy group (ten patients (50.0%) vs. five
patients (22.7%), χ2 p= 0.065). The total and other indi-
vidual PASQ scores did not differ significantly between the
groups after treatment with PAS-LAR. Similarly, neither
the AcroQoL global nor any of the subdimensions differed
significantly between the combination and monotherapy
group after treatment with PAS-LAR. AcroQoL and PASQ
scores in the treatment groups were comparable with the
total cohort, with exception of the change in fatigue, which
only presented in the combination group (not shown).
Correlations
The correlations between changes in parameters of QoL and
changes in biochemical parameters in the total cohort are
presented in Fig. 3. Neither the change in IGF-1 nor the
baseline and/or change in GH levels correlated with changes
in QoL in the total cohort (not shown). In contrast, changes
in sKlotho levels correlated with PASQ total (r= 0.35, p=
0.012, Fig. 3a), headache (r= 0.28, p= 0.048), osteoar-
thralgia (r= 0.46, p= 0.00080, Fig. 3b), and soft tissue
swelling score (0.29, p= 0.041), which are all QoL entities
that reflect increased GH actions. In addition, changes in
sKlotho levels correlated with the observed improvements
in QoL by the AcroQoL global (r=−0.35, p= 0.012,
Fig. 3c) and the physical subdimension (r=−0.34, p=
0.017, Fig. 3d). PASQ fatigue (r= 0.23, p= 0.10) and
excessive perspiration (r= 0.24, p= 0.091), and the Acro-
QoL personal relations subdimension (r=−0.26, p=
0.061) all tended to correlate with changes in sKlotho levels
but failed to reach significance. At last, changes in sKlotho
were positively correlated with changes in total IGF-1 levels
(r= 0.31, p= 0.023, adjusted for age, Fig. 3e).
Soluble Klotho and reasons to continue PAS-LAR
therapy
At the end of study, 61.1% (33/54) patients chose to con-
tinue PAS-LAR treatment with or without PEGV, instead of
switching back to their previous first-generation SRL and
PEGV combination treatment regimen. The two most fre-
quently reported reasons for continuation with PAS-LAR
were the improvement in fatigue and headache symptoms
(20/33, 60.6%), followed by the achieved PEGV dose
reduction or discontinuation (13/33, 39.4%). The most
frequently reported reason for discontinuing PAS-LAR was
the use of antidiabetic medications (17/21, 81.0%) followed
by experiencing no improvement in QoL (3/21, 14.3%) or
newly occurring ECG abnormalities (1/21, 4.7%).
All patients were stratified according to their decision on
whether to continue or discontinue PAS-LAR treatment and
subsequently compared with sKlotho concentrations.
Changes in sKlotho levels were inversely correlated with
the achieved PEGV dose reduction and discontinuation
during 9 months of PAS-LAR treatment (r=−0.38, p=
0.0049). In addition, the achieved PEGV dose reduction
tended to correlate with sKlotho levels during 9 months of
Table 2 Quantitative changes in QoL induced by the switch to PAS-
LAR monotherapy and in combination with PEGV combined
Baseline
median (IQR)
n= 51
PAS-LAR
(9 months)
median (IQR)
n= 51
P values
PASQ total 14.0 (7.0–21.3) 10.0 (6.0–19.0) 0.090
PASQ headache 1.0 (0.0–3.0) 1.0 (0.0–2.0) 0.014
PASQ excessive
perspiration
2.0 (0.0–3.8) 2.0 (0.0–4.0) ns
PASQ
osteoarthralgia
3.5 (1.0–5.0) 3.0 (1.5–4.5) ns
PASQ fatigue 3.0 (2.0–5.0) 3.0 (1.5–5.0) 0.0074
PASQ soft tissue
swelling
2.0 (0.0–3.0) 1.0 (0.0–3.0) ns
PASQ paresthesia 1.0 (0.0–3.0) 1.0 (0.0–3.0) ns
PASQ overall
health status
3.0 (2.0–6.0) 3.0 (2.0–5.0) ns
AcroQoL global (%) 66.4 (60.0–77.3) 71.8 (65.0–82.7) ≤0.0001
AcroQoL
physical (%)
31.4 (25.7–35.7) 35.7 (29.3–40.0) ≤0.0001
AcroQoL
psychological (%)
70.7 (64.3–78.6) 72.9 (65.0–85.7) 0.0051
AcroQoL personal
relations (%)
80.0 (68.6–88.6) 82.9 (71.4–88.6) ns
AcroQoL
appearance (%)
62.9 (54.3–77.1) 65.7 (54.3–77.1) 0.0095
AcroQoL Acromegaly Quality of Life, IQR interquartile range, ns not
significant, PAS-LAR pasireotide long-acting release, PASQ Patient-
Assessed Acromegaly Symptom Questionnaire, PEGV pegvisomant
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PAS-LAR treatment (r=−0.24, p= 0.089) but failed to
reach significance.
Discussion
The most striking finding of our study was that serum
sKlotho correlates with QoL, while GH and IGF-1 do not.
In our study the improvement of QoL correlated with the
improvement in serum sKlotho (i.e., a greater absolute
reduction in sKlotho). This is line with previous data sug-
gesting that sKlotho levels are elevated in patients with
active acromegaly and decrease toward the normal range
after surgery [14, 15] and/or first-generation SRLs [16, 17].
This suggests that sKlotho might be a potentially useful
biomarker in assessing QoL in acromegaly patients. Fur-
thermore, we observed that improvement in serum sKlotho
corresponds with improvement in serum IGF-1. This is in
line with the previous study of Anand et al. that showed that
IGF-1 and sKlotho levels decrease to a similar extent during
surgery alone or in combination with medical treatment
[17]. Thus, it may also provide clinicians with another tool,
apart from GH and IGF-1, to assess disease activity in
acromegaly. This observation confirms and builds upon
previous studies [12, 14, 15], proposing sKlotho to be an
independent marker of disease severity in acromegaly
besides GH and IGF-1. It has previously been stated that
serum GH and IGF-1 levels, assessed by the commercially
available assays, do not correlate well enough with the
patients’ perception of QoL to use them for defining proper
biochemical control [7–11, 23]. Interestingly, although the
disease-specific osteoarthralgia and soft tissue swelling
score remained unimproved during 9 months with PAS-
LAR, the symptoms were significantly correlated to sKlotho
but not to IGF-1 or GH.
Our results are in contrast to a previous study by Var-
ewijck et al., which failed to detect significant relations
between sKlotho and any of the QoL measurements in
treatment-naive acromegaly patients, while both studies
employed the same assay to assess sKlotho [32]. However,
Fig. 3 Correlations between the
change in sKlotho and PASQ
total (a) and PASQ
osteoarthralgia (b). Correlations
between the change in sKlotho
and AcroQoL global (c) and
AcroQoL physical dimension
(d). e Depicts the correlation
between change in sKlotho and
change in total IGF-1 levels
adjusted for age. AcroQoL
Acromegaly Quality of Life,
IGF-1 insulin-like growth factor
1, sKlotho soluble Klotho,
PASQ Patient-Assessed
Acromegaly Symptom
Questionnaire
Endocrine
only one sKlotho measurement was performed in the study
of Varewijck et al. and the small number of included
patients (n= 15) may have increased the risk for a type 2
error [32]. Indeed, in the present study we measured
sKlotho during first-generation SRL and PEGV combina-
tion treatment at baseline and after switching to PAS-LAR
treatment alone or in combination with PEGV. In contrast to
naive acromegaly patients, the patients included in the
present study may show long-term effects of treatment, such
as postirradiation effects or hypopituitarism.
Soluble Klotho concentrations appear to be a useful
marker of QoL in acromegaly patients, but the underlying
mechanisms have to be investigated. Although our data
suggest a predominant role for sKlotho in the intricate
regulation of the GH-IGF-1 axis, the underlying mechan-
isms whereby it stimulates the production of sKlotho
remains to be elucidated. Further, it is conceivable that
sKlotho represents an adaptation mechanism by which the
body attenuates increased IGF-1 actions. It has been found
that sKlotho can inhibit the activation of the IGF-1 receptor
(IGF-1R) in a dose-dependent manner [19, 33]. Subse-
quently, sKlotho-induced IGF-1R resistance is achieved by
suppressing either the ligand-stimulated autopho-
sphorylation and the activation of signaling events down-
stream of the IGF-1R [19, 34]. To the extent that sKlotho
expression dampens IGF-1 actions in acromegaly patients,
it might be a more reliable parameter for QoL than serum
IGF-1, but this remains to be further studied.
A second finding of our study is that after switching to
PAS-LAR therapy a significant improvement in QoL was
observed without a significant change in IGF-1 levels.
Although in some individuals (i.e., in the PAS-LAR
monotherapy group), IGF-1 levels markedly decreased
during PAS-LAR treatment, in most patients, IGF-1 levels
did not decrease significantly. In contrast, during PAS-LAR
treatment a significant increase in IGF-1 levels was
observed in the combination therapy group compared with
baseline. In addition, normalization of IGF-1 levels during
PAS-LAR treatment was not achieved by all patients, while
at baseline of the study IGF-1 concentrations within the
age-adjusted normal range had been measured during
combination treatment of first-generation SRL and PEGV.
Our results confirm that relative lower or normalized levels
of serum IGF-1 do not necessarily have consequences for a
change in QoL [7–11]. This observation challenges the
current strategy of using PAS-LAR as second or third-line
monotherapy when IGF-1 levels have failed to normalize
during first-generation SRL monotherapy, while a clinically
relevant tumor remnant is still visible imaging and/or there
is evidence for tumor growth [35].
In both groups we observed a significant decrease in GH
levels during PAS-LAR treatment in comparison with
baseline [1, 2]. We have previously assumed that this is
related to the reduction or discontinuation of the PEGV
dose [2]. This assumption is supported by the observed
significantly lower GH levels in the PAS-LAR mono-
therapy group in comparison with the combination therapy
group during follow-up [2]. In addition, the decreased GH
levels may have had an impact on disease activity as well.
A third finding of our study is that most changes in QoL,
which are possibly related to GH secretion, did not differ
between patients using PAS-LAR alone and in combination
with PEGV apart from one exception: a significant
improvement in fatigue symptoms only presented in the
combination group. However, quantitative changes in this
subdimension did not differ significantly between the groups.
Soluble Klotho may be both an indicator of disease
activity as well as a marker of QoL. Soluble Klotho levels
at follow-up did not differ significantly between the two
groups, possibly explaining why QoL did not differ sig-
nificantly between the two groups. Moreover, total and
age-dependent serum IGF-1 levels were significantly
higher in patients treated with combination therapy com-
pared with patients treated with monotherapy patients,
possibly explaining why GH-dependent parameters of
QoL did not differ between the two groups either.
Unfortunately, the study was not powered to assess dif-
ferences in QoL between monotherapy and combination
therapy. In addition, the duration of follow-up of our study
was relatively short, and some GH-mediated effects may
become manifest only after long-term co-administration of
PEGV therapy. Therefore, it is possible that studies in
larger populations with a longer follow-up may show a
difference in improvement in QoL between the two
groups. Nevertheless, we did observe improvements in
QoL in the total cohort that correlated well with other GH-
dependent parameters such as headache, soft tissue swel-
ling, and the AcroQoL physical subdimension, suggesting
that in these patients, integrated GH action remains ele-
vated despite normal IGF-1 levels.
It should be stressed that our study has several limita-
tions. First of all, patients participating in the study could
have a more proactive attitude, which helped them to
achieve improvements in QoL in comparison with the
general acromegaly population (i.e., selection bias). We
should mention here that most patients remained bio-
chemically controlled after switching to PAS-LAR therapy
and correlations with IGF-1 levels were limited only for
normal range IGF-1 levels. Secondly, general well-being
might have increased in response to a reduction in the
number of injections of PEGV that the patients received
during the study in comparison with their previous treat-
ment regimen. However, this may not account for differ-
ences in the change of QoL between both treatment groups.
Lastly, participants were required to visit the hospital more
frequently, which may influence improvements in QoL. All
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of these factors might have affected the patients’ perception
of QoL.
What further complicates the interpretation of our results
is the precarious understanding of sKlotho in the clinic.
Although the sKlotho assay provides a reproducible method
for quantitatively assessing sKlotho, it currently does not
have a clear place in the clinical routine. An important step
toward the implementation of measuring serum sKlotho in
clinical routine is to run the assays on an automated system.
Moreover, introduction of the standardization of sKlotho
assays should be implemented and normal ranges of sKlo-
tho in healthy controls should be developed.
Current consensus statements mainly aim at normalizing
IGF-1 to the age-adjusted normal range [35], while more or
less neglecting any signs and symptoms still present after
IGF-1 (and GH) normalization. However, from a patient’s
perspective, normalization of serum IGF-1 levels may be
insufficient to treat his or her symptoms and signs. There-
fore, we should include improvement of QoL as a treatment
goal on top of the normalization of biochemical markers.
In conclusion, we observed significant improvements in
QoL in biochemically well-controlled acromegaly patients
during first-generation SRLs in combination with PEGV
after switching to PAS-LAR treatment. We also found that
sKlotho showed a positive correlation with improvements
in QoL. Surprisingly, improvements in QoL were not
accompanied by a significant change in IGF-1 levels, which
challenges the importance of serum IGF-1 as a reliable
parameter to monitor QoL from a patient’s perspective.
Soluble Klotho concentrations may be a new useful marker
of QoL in acromegaly patients which should be further
studied.
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